Trifluoroacetic acid → 2-[3-(3-Methyl-isoxazol-5-yl)-phenyl]-8-morpholin-4-yl-4-oxo-4,5-dihydro-3H-benzo[b][1,4]diazepine-7-carbonitrile
反応式
C(OC(=O)[NH:7][C:8]1[CH:13]=[C:12]([N:14]2[CH2:19][CH2:18][O:17][CH2:16][CH2:15]2)[C:11]([C:20]#[N:21])=[CH:10][C:9]=1[NH:22][C:23](=[O:39])[CH2:24][C:25]([C:27]1[CH:32]=[CH:31][CH:30]=[C:29]([C:33]2[O:37][N:36]=[C:35]([CH3:38])[CH:34]=2)[CH:28]=1)=O)(C)(C)C.C(O)(C(F)(F)F)=O>C(Cl)Cl>[CH3:38][C:35]1[CH:34]=[C:33]([C:29]2[CH:28]=[C:27]([C:25]3[CH2:24][C:23](=[O:39])[NH:22][C:9]4[CH:10]=[C:11]([C:20]#[N:21])[C:12]([N:14]5[CH2:19][CH2:18][O:17][CH2:16][CH2:15]5)=[CH:13][C:8]=4[N:7]=3)[CH:32]=[CH:31][CH:30]=2)[O:37][N:36]=1参加物
4
反応物 2
生成物 1
試薬・触媒・溶媒 1
実験手順
The title compound was prepared from (4-cyano-2-{3-[3-(3-methyl-isoxazol-5-yl)-phenyl]-3-oxo-propionylamino}-5-morpholin-4-yl-phenyl)-carbamic acid tert-butyl ester (Example M42) (0.39 g, 0.71 mmol) by treatment with TFA in CH2Cl2 according to the general procedure N. Obtained as a light yellow solid (215 mg, 70%).